• In GEICAM 2006-10, the addition of fulvestrant at 250 mg/d to anastrozole did not improve 5-year disease-free survival over anastrozole alone (91.0% vs 90.8%). 
• “Immune induction” with chemotherapy or radiotherapy appeared to enhance response to nivolumab in women with metastatic triple-negative breast cancer.
• A four-gene signature combining expression levels of genes associated with immune activation predicted the residual level of tumor-infiltrating lymphocytes after neoadjuvant chemotherapy for triple-negative breast cancer. High expression of this gene signature, compared to low expression, was associated with improved disease-free and overall survival. 
• In metastatic triple-negative patients in the KEYNOTE-086 trial, the level of tumor-infiltrating lymphocytes was significantly associated with response to pembrolizumab, particularly in the first-line setting.
• Neratinib, a dual inhibitor of HER2 and EGFR, significantly improved invasive disease–free survival in early-stage HER2-positive breast cancer previously treated with 1 year of trastuzumab, according to 5-year follow-up of the phase III ExteNET trial. The benefits were more robust in hormone receptor–positive patients.
• Results of the phase III ICON8 trial reaffirmed that 3-weekly paclitaxel remains the standard of care for first-line therapy of ovarian cancer. Weekly dose-dense chemotherapy with paclitaxel was tolerable but did not improve progression-free survival compared with every-3-week paclitaxel (standard of care) in this setting. ■